可溶性ST2在肺动脉高压中的研究及应用进展
|
摘要
肺动脉高压是一种引起右心室肥厚,最终导致右心衰竭甚至死亡的严重心血管疾病。作为心血管疾病的新型生物标志物,可溶性ST2被认为与肺动脉高压发病及预后相关。现对可溶性ST2在肺动脉高压中的研究及应用进展做一综述。
Pulmonary arterial hypertension is a serious cardiovascular disease that causes right ventricular hypertrophy,leading to right heart failure and even death.As a new biomarker of cardiovascular diseases,soluble ST2 is believed to be related to the incidence and prognosis of pulmonary arterial hypertension.This paper reviews the research and application of soluble ST2 in pulmonary arterial hypertension.
Pulmonary arterial hypertension is a serious cardiovascular disease that causes right ventricular hypertrophy,leading to right heart failure and even death.As a new biomarker of cardiovascular diseases,soluble ST2 is believed to be related to the incidence and prognosis of pulmonary arterial hypertension.This paper reviews the research and application of soluble ST2 in pulmonary arterial hypertension.
引文
[1]Yancy CW,Jessup M,Bozkurt B,et al.2013 ACCF/AHA guideline for the management of heart failure:executive summary:a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J].Circulation,2013,128(16):1810-1852.
[2]Tominaga S.A putative protein of a growth specific c DNA from BALB/c-3T3cells is highly similar to the extracellular portion of mouse interleukin 1 receptor[J].FEBS Lett,1989,258(2):301-304.
[3]Gachter T,Werenskiold AK,Klemenz R.Transcription of the interleukin-1 receptor-related T1 gene is initiated at different promoters in mast cells and fibroblasts[J].J Biol Chem,1996,271(1):124-129.
[4]Schmitz J,Owyang A,Oldham E,et al.IL-33,an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type2-associated cytokines[J].Immunity,2005,23(5):479-490.
[5]Demyanets S,Kaun C,Pentz R,et al.Components of the interleukin-33/ST2system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature[J].J Mol Cell Cardiol,2013,60:16-26.
[6]Liu J,Wang W,Wang L,et al.IL-33 initiates vascular remodelling in hypoxic pulmonary hypertension by up-regulating HIF-1alpha and VEGF expression in vascular endothelial cells[J].EBio Medicine,2018,33:196-210.
[7]Shao D,Perros F,Caramori G,et al.Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension[J].Biochem Biophys Res Commun,2014,451(1):8-14.
[8]Veeraveedu PT,Sanada S,Okuda K,et al.Ablation of IL-33 gene exacerbate myocardial remodeling in mice with heart failure induced by mechanical stress[J].Biochem Pharmacol,2017,138:73-80.
[9]Sanada S,Hakuno D,Higgins LJ,et al.IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system[J].J Clin Invest,2007,117(6):1538-1549.
[10]Mildner M,Storka A,Lichtenauer M,et al.Primary sources and immunological prerequisites for s ST2 secretion in humans[J].Cardiovasc Res,2010,87(4):769-777.
[11]Carlomagno G,Messalli G,Melillo RM,et al.Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension[J].Int J Cardiol,2013,168(2):1545-1547.
[12]Scherzer R,Shah SJ,Secemsky E,et al.Association of biomarker clusters with cardiac phenotypes and mortality in patients with HIV infection[J].Circ Heart Fail,2018,11(4):e4312.
[13]Placido R,Cortez-Dias N,Robalo MS,et al.Prognostic stratification in pulmonary hypertension:a multi-biomarker approach[J].Rev Port Cardiol,2017,36(2):111-125.
[14]Zheng YG,Yang T,He JG,et al.Plasma soluble ST2 levels correlate with disease severity and predict clinical worsening in patients with pulmonary arterial hypertension[J].Clin Cardiol,2014,37(6):365-370.
[15]Agoston-Coldea L,Lupu S,Hicea S,et al.Serum levels of the soluble IL-1 receptor family member ST2 and right ventricular dysfunction[J].Biomark Med,2014,8(1):95-106.
[16]Chida A,Sato H,Shintani M,et al.Soluble ST2 and N-terminal pro-brain natriuretic peptide combination.Useful biomarker for predicting outcome of childhood pulmonary arterial hypertension[J].Circ J,2014,78(2):436-442.
[2]Tominaga S.A putative protein of a growth specific c DNA from BALB/c-3T3cells is highly similar to the extracellular portion of mouse interleukin 1 receptor[J].FEBS Lett,1989,258(2):301-304.
[3]Gachter T,Werenskiold AK,Klemenz R.Transcription of the interleukin-1 receptor-related T1 gene is initiated at different promoters in mast cells and fibroblasts[J].J Biol Chem,1996,271(1):124-129.
[4]Schmitz J,Owyang A,Oldham E,et al.IL-33,an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type2-associated cytokines[J].Immunity,2005,23(5):479-490.
[5]Demyanets S,Kaun C,Pentz R,et al.Components of the interleukin-33/ST2system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature[J].J Mol Cell Cardiol,2013,60:16-26.
[6]Liu J,Wang W,Wang L,et al.IL-33 initiates vascular remodelling in hypoxic pulmonary hypertension by up-regulating HIF-1alpha and VEGF expression in vascular endothelial cells[J].EBio Medicine,2018,33:196-210.
[7]Shao D,Perros F,Caramori G,et al.Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension[J].Biochem Biophys Res Commun,2014,451(1):8-14.
[8]Veeraveedu PT,Sanada S,Okuda K,et al.Ablation of IL-33 gene exacerbate myocardial remodeling in mice with heart failure induced by mechanical stress[J].Biochem Pharmacol,2017,138:73-80.
[9]Sanada S,Hakuno D,Higgins LJ,et al.IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system[J].J Clin Invest,2007,117(6):1538-1549.
[10]Mildner M,Storka A,Lichtenauer M,et al.Primary sources and immunological prerequisites for s ST2 secretion in humans[J].Cardiovasc Res,2010,87(4):769-777.
[11]Carlomagno G,Messalli G,Melillo RM,et al.Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension[J].Int J Cardiol,2013,168(2):1545-1547.
[12]Scherzer R,Shah SJ,Secemsky E,et al.Association of biomarker clusters with cardiac phenotypes and mortality in patients with HIV infection[J].Circ Heart Fail,2018,11(4):e4312.
[13]Placido R,Cortez-Dias N,Robalo MS,et al.Prognostic stratification in pulmonary hypertension:a multi-biomarker approach[J].Rev Port Cardiol,2017,36(2):111-125.
[14]Zheng YG,Yang T,He JG,et al.Plasma soluble ST2 levels correlate with disease severity and predict clinical worsening in patients with pulmonary arterial hypertension[J].Clin Cardiol,2014,37(6):365-370.
[15]Agoston-Coldea L,Lupu S,Hicea S,et al.Serum levels of the soluble IL-1 receptor family member ST2 and right ventricular dysfunction[J].Biomark Med,2014,8(1):95-106.
[16]Chida A,Sato H,Shintani M,et al.Soluble ST2 and N-terminal pro-brain natriuretic peptide combination.Useful biomarker for predicting outcome of childhood pulmonary arterial hypertension[J].Circ J,2014,78(2):436-442.